Arjan Gower, MD, MS

Thoracic Medical Oncologist and Researcher @UCLA

[AVEO Oncology @AVEOOncology]

Dr. Arjan Gower Wins Cary Presant Young Investigator Award - Congratulations to Dr. Arjan Gower, MD, MS of UCLA Health, who was awarded the #CaryPresantYoungInvestigatorAward, sponsored by @AVEOOncology, an LG Chem company, at the #MOASC 2026 Annual Oncology Leadership & Research Summit in Newport Beach, CA. The award reflects our ongoing commitment to supporting the next generation of scientific leaders and will include a $25,000 grant to advance Dr. Gower's groundbreaking research. Congratulations again to you, Dr. Gower, on this well-deserved recognition for helping shape the future of cancer care! You can read more about the details of his winning project in lung cancer treatment and the award ceremony here: https://t.co/c1uwe9aNpt

@MOASC_Office ; @oncologytube

#MOASC2026 #YoungInvestigatorAward #CaryPresantAward #CancerResearch #PrecisionOncology #Oncology

[Exon 20 Group, a multistakeholder organization @Exon20Group]

We are thrilled about Taiho Oncology's zipalertinib EAP for EGFR exon 20 patients in the U.S. Zipalertinib is formerly known as CLN-O81 or TAS6417. Patients must have received available standard of care (plat-based chemo +/- amivantamab). Our EGFR Exon 20 Warriors at the Exon 20 Group intend to keep Taiho and Parexel very busy! U.S. oncologists may submit EAP requests to [email protected] https://t.co/PgNZ2x2NcP

[Arjan Gower, MD, MS @ArjanGower]

@DrewMoghanaki Gives some scientific rationale to radiate oligometastatic lesions

[Sumanta K. Pal, MD, FASCO @montypal]

Are you a 2nd or 3rd year heme-onc fellow in the #SoCal area? We at @MOASC_Office have created something for you! Consider applying to the inaugural #MOASC #NextGen Program, designed to pair the best & brightest fellows in our region with experienced faculty in a year-long curriculum aimed at fostering career development. Faculty will be derived from our board which includes @PatelOncology, @minasedrakmd, @hoperugo, @ChawlaNeal, @DrJZell, @christine_lovly & so many more!

[David Gandara @drgandara]

Congratulations to Tina Cascone & colleagues on strong work in plasma ctDNA determination of MRD. Clearly prognostic. Clearance association with pCR informative. Ongoing trials such as INSIGHT will help determine benefit of postoperative immunotherapy component in those with pCR

[Arjan Gower, MD, MS @ArjanGower]

@JordynSilvs @SGO_org Amazing work!

[Oncology Tube @oncologytube]

🎉 Big congratulations to Dr. @ArjanGower @UCLA for winning the $25,000 Cary Presant Young Investigator Award at @MOASC_Office 2026!

His research on methylome biomarkers for Dato-DXd in lung cancer is exactly the kind of innovation we need.
👉 https://t.co/zOngyU2Bd0

Thank you @AVEOOncology for sponsoring & @MOASC_Office for supporting the next generation!

@montypal @BrendonStilesMD @lung_fund @Latinamd @bmassutis @LungCancerEu @LauraJBook @lqvca77674249 @samir_barghout @oncoexpertrl @dina4patients @geunhou1 @cityofhopeoc @ACPUK @AdamJanuszewski @AnaVManana @BTOGorg @BairdAM @BertrandBio @CancerInstIRE @Donegal_SAL @DrSanjayPopat @FMLM_UK @HerediaOncologo @Kikamorox @LinksCancer @LungCommunity @MarceloCorassa @ZSFGCare @tcddublin @OncoAlert

#MOASC2026 #YoungInvestigatorAward #CaryPresantAward #LungCancer

[Arjan Gower, MD, MS @ArjanGower]

@jgong15 Wow congrats!!

[Dr. Estela Rodriguez @Latinamd]

#ELCC26 Another population-based study showing the clear benefit of #lungcancer screening in adults 40-74 including never smokers in China.

N=12,000
followup 7 yrs
⬇️Significantly lower risk of LC deaths (HR 0.45)
⬆️ Increased mortality benefit in women (HR 0.28)
⬆️more Stage I LC cases compared to control population. (85% vs 25%)
#screeningsaveslives
🎙️Dr. Caichen Li

[Giannis Mountzios @g_mountzios]

#ELCC26 @MartinReck2 on KN671 exploratory analysis of patients without pCR

5-year EFS 43% vs 25% , HR =0,69, 95%CI 0.57-0.83)

[MOASC @MOASC_Office]

Congratulations to Dr. Arjan Gower @ArjanGower @UCLAHealthJCCC on receiving the 2026 Cary Presant Young Investigator Award from MOASC for his work on predictive pharmacodynamics biomarkers using circulating tumor DNA in advanced lung cancer! Huge thanks to @AVEOOncology for their unwavering support of this YIA and MOASC over the years! #MOASCAnnualSummit2026

[Arjan Gower, MD, MS @ArjanGower]

@MOASC_Office @UCLAHealthJCCC @AVEOOncology I am deeply grateful to be the recipient of this year’s Cary Presant Young Investigator Award from @MOASC_Office to support my research investigating predictive biomarkers of response to datopotamab deruxtecan

[UCLA Health @UCLAHealth]

Three specialties. One robot. UCLA Health performed a rare combined heart-lung surgery that most centers can't offer, giving a 77-year-old patient her best shot at recovery.

[Arjan Gower, MD, MS @ArjanGower]

@minasedrakmd Congratulations!!

[Drew Moghanaki @DrewMoghanaki]

From #WCLC25 in Barcelona to #ASTRO25 in San Francisco, our team is presenting these data once again on in-field progression, with an outstanding narration by Shannon Nesbitt, who is pursuing a career in thoracic surgery. https://t.co/jOmnbgg4dx

[Oncology Times @OncologyTimes]

Arjan Gower, MD, MS, a hematologist/oncologist at the @UCLAHealthJCCC, has received a research grant from the @NCCN to study a promising new targeted therapy for early-stage non-small cell #lungcancer with rare EGFR mutations. https://t.co/QDe1SfEb0d

[Arjan Gower, MD, MS @ArjanGower]

Published today: Prevalence of EGFR mutations in ovarian cancer published in @JCOPO_ASCO
Very rare but targetable. Patient with previously treated EGFR L858R ovarian cancer had durable response with osimertinib

https://t.co/Dm4yrpNlcG

[Arjan Gower, MD, MS @ArjanGower]

Come by my poster “identification of deruxtecan-induced methylome signature in NSCLC cell lines” at #WCLC25 translational research aimed ultimately at elucidating a predictive on treatment signature for deruxtecan based ADCs

[Arjan Gower, MD, MS @ArjanGower]

Barcelona #WCLC25 with my UCLA thoracic onc colleagues after Jonathan Goldman gave the Presidential abstract this morning

[Arjan Gower, MD, MS @ArjanGower]

@DrewMoghanaki @FordePatrick @DoctorJSpicer @MARIANOPROVENCI @JieDengMDPhD @LeciaSequist @max_diehn @CharuAggarwalMD @n8pennell @JackWestMD It’s always been an imperfect predictor but it’s the best we have right now. I don’t think any single analyte will ever be perfect

[Arjan Gower, MD, MS @ArjanGower]

@DrewMoghanaki @FordePatrick @DoctorJSpicer @MARIANOPROVENCI @JieDengMDPhD @LeciaSequist @max_diehn @CharuAggarwalMD @n8pennell @JackWestMD Still 17 percent of people who are PD-L1 neg achieve path CR with neoadjucant chemoIO (vs 3% with chemo) and it’s important to figure out why biologically certain patients benefit